As a phase III blow-up brings Sage Therapeutics’ run of success to an end, the company’s post-hoc analyses fail to reassure investors that its depression project has a…
Biogen’s clinical-stage pipeline carries little weight, and encouraging data in lupus is unlikely to change that.
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
Supernus needs something to fill the gap left by its faltering epilepsy drug Trokendi XR, but SPN-810 isn’t it.
The amyloid-beta project is to be filed for Alzheimer’s, and Biogen’s market cap regains the $15bn it lost in March.
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Sage's big depression readout looms, while Biogen hopes for a mid-stage hit in lupus.